Patent intelligence · US
US 10953018
Emulsion formulations of aprepitant
Emulsion formulations of aprepitant
Patent details — US 10953018
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 23, 2021
- Expiration
- Mar 18, 2041
- Applicant
- Heron Therapeutics, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/5377, A61K31/573, A61K47/10
Quick answer
US 10953018 (Emulsion formulations of aprepitant) is held by Heron Therapeutics, Inc.. Status: granted. Granted Mar 23, 2021. Expires Mar 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Heron Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/5377, A61K31/573, A61K47/10, A61K47/12, A61K47/18
More from Heron Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318376
Compositions of a polyorthoester and an aprotic solvent
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11844837
Compositions of a polyorthoester and an organic acid excipient
granted -
US 11744800
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11413350
Long-acting polymeric delivery systems
granted
Frequently asked questions
What is US patent 10953018?
US 10953018 (Emulsion formulations of aprepitant) is held by Heron Therapeutics, Inc.. Status: granted. Granted Mar 23, 2021. Expires Mar 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10953018?
Heron Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 46 pharmaceutical patents for this assignee.
When does US 10953018 expire?
Our index shows an expiration date of Mar 18, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.